Zhejiang Huahai Pharmaceutical announced that its subsidiary Shanghai Huao Tai Biological Pharmaceutical Co., Ltd. has obtained approval from the New Zealand Medicines and Medical Instruments Safety Authority and the Health and Disability Ethics Committee to conduct Phase I clinical trials of HB56 injection.
华海药业：子公司HB56注射液获新西兰临床试验许可
Zhejiang Huahai Pharmaceutical: Subsidiary HB56 injection granted clinical trial approval in New Zealand.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated